{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T13:28:39Z","timestamp":1781270919302,"version":"3.54.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To study the impact of hyperuricemia on clinical presentation, severity, and associated comorbidities of psoriatic arthritis (PsA).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Retrospective bicentric case\u2013control study performed in Strasbourg and Colmar, France, from 2009 to 2019. Patients with PsA (according to ICD-10 coding) and at least one available serum urate (SU) measurement were included. Demographic, comorbidities, clinical, and radiographic data were collected. Hyperuricemia was defined as SU level\u2009\u2265\u2009360\u00a0\u00b5mol\/L.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We included 242 patients: 73 (30.2%) had hyperuricemia and 15 (6.2%) met 2015 ACR\/EULAR criteria for gout. On univariate analysis, as compared with normo-uricemic patients, hyperuricemic patients were more frequently male (72.6% vs 39.1%, <jats:italic>p<\/jats:italic>\u2009=\u20091.6\u2009\u00d7\u200910<jats:sup>\u22126<\/jats:sup>) with higher body mass index (30.9 vs 28.7\u00a0kg\/m<jats:sup>2<\/jats:sup>, <jats:italic>p<\/jats:italic>\u2009=\u20090.015) and more comorbidities (Charlson comorbidity index: 2.6 vs 1.8, <jats:italic>p<\/jats:italic>\u2009=\u20090.005). PsA started at an older age (47.5 vs 43\u00a0years, <jats:italic>p<\/jats:italic>\u2009=\u20090.016) was more polyarticular (56.2% vs 41.9%, <jats:italic>p<\/jats:italic>\u2009=\u20090.049) than axial (9.6% vs 22.8%, <jats:italic>p<\/jats:italic>\u2009=\u20090.019) and more destructive (52.8% vs 37.4%, <jats:italic>p<\/jats:italic>\u2009=\u20090.032). PsA patients with joint destruction more frequently had hyperuricemia than did others (37.6% vs 25.8%, <jats:italic>p<\/jats:italic>\u2009=\u20090.047). Multivariable analysis confirmed the association of hyperuricemic PsA with peripheral joint involvement (odds ratio 2.98; 95% confidence interval 1.15\u20137.75; <jats:italic>p<\/jats:italic>\u2009=\u20090.025) and less good response to treatment (0.35; 0.15\u20130.87; <jats:italic>p<\/jats:italic>\u2009=\u20090.024).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Patients with hyperuricemic PsA show poorer response to PsA treatment and have more peripheral and destructive joint damage than normo-uricemic patients.\n<jats:table-wrap><jats:table><jats:tbody>\n                      <jats:tr>\n                        <jats:td colspan=\"2\"><jats:bold>Key Points<\/jats:bold>\u2022 <jats:italic>Gout and psoriatic arthritis (PsA) can co-exist in the same patient.<\/jats:italic>\u2022 <jats:italic>Monosodium urate crystals might have a deleterious impact on PsA.<\/jats:italic>\u2022 <jats:italic>Hyperuricemic PsA is more polyarticular, less frequently axial, and more destructive than normo-uricemic PsA.<\/jats:italic>\u2022 <jats:italic>PsA with hyperuricemia should lead to more personalized medicine.<\/jats:italic><\/jats:td>\n                      <\/jats:tr>\n                    <\/jats:tbody><\/jats:table><\/jats:table-wrap><\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10067-022-06061-x","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T19:03:36Z","timestamp":1642705416000},"page":"1421-1429","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Psoriatic arthritis with hyperuricemia: more peripheral, destructive, and challenging to treat"],"prefix":"10.1007","volume":"41","author":[{"given":"L.","family":"Widawski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Fabacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Spielmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JE.","family":"Gottenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sibilia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PM.","family":"Duret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Messer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Felten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,20]]},"reference":[{"key":"6061_CR1","doi-asserted-by":"publisher","unstructured":"Felten R, Duret P-M, Gottenberg J-E, et al. At the crossroads of gout and psoriatic arthritis: \u2018psout\u2019. Clin Rheumatol Published Online First: 15 February 2020.https:\/\/doi.org\/10.1007\/s10067-020-04981-0","DOI":"10.1007\/s10067-020-04981-0"},{"key":"6061_CR2","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD (2017) Psoriatic arthritis. N Engl J Med 376:957\u2013970. https:\/\/doi.org\/10.1056\/NEJMra1505557","journal-title":"N Engl J Med"},{"key":"6061_CR3","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1016\/S0140-6736(18)31366-7","volume":"391","author":"R Barnett","year":"2018","unstructured":"Barnett R (2018) Gout. The Lancet 391:2595. https:\/\/doi.org\/10.1016\/S0140-6736(18)31366-7","journal-title":"The Lancet"},{"key":"6061_CR4","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s10238-018-0500-y","volume":"18","author":"NT Costa","year":"2018","unstructured":"Costa NT, Scavuzzi BM, Iriyoda TMV et al (2018) Metabolic syndrome and the decreased levels of uric acid by leflunomide favor redox imbalance in patients with rheumatoid arthritis. Clin Exp Med 18:363\u2013372. https:\/\/doi.org\/10.1007\/s10238-018-0500-y","journal-title":"Clin Exp Med"},{"key":"6061_CR5","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3899\/jrheum.170384","volume":"45","author":"R AlJohani","year":"2018","unstructured":"AlJohani R, Polachek A, Ye JY et al (2018) Characteristic and outcome of psoriatic arthritis patients with hyperuricemia. J Rheumatol 45:213\u2013217. https:\/\/doi.org\/10.3899\/jrheum.170384","journal-title":"J Rheumatol"},{"key":"6061_CR6","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1136\/annrheumdis-2019-eular.1674","volume":"78","author":"AB Arevalo","year":"2019","unstructured":"Arevalo AB, Haddadin F, Contreras G et al (2019) Sat0371 Cardiovascular impact of hyperuricemia in patients with psoriatic arthritis. Ann Rheum Dis 78:1268\u20131268. https:\/\/doi.org\/10.1136\/annrheumdis-2019-eular.1674","journal-title":"Ann Rheum Dis"},{"key":"6061_CR7","first-page":"34","volume":"72","author":"KG Golov","year":"1994","unstructured":"Golov KG, Ivanov OL, Balkarov IM et al (1994) Clinical significance of hyperuricemia in psoriasis. Klin Med (Mosk) 72:34\u201336","journal-title":"Klin Med (Mosk)"},{"key":"6061_CR8","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1136\/annrheumdis-2014-206410","volume":"75","author":"C-F Kuo","year":"2016","unstructured":"Kuo C-F, Grainge MJ, Mallen C et al (2016) Comorbidities in patients with gout prior to and following diagnosis: case-control study. Ann Rheum Dis 75:210\u2013217. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206410","journal-title":"Ann Rheum Dis"},{"key":"6061_CR9","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/1756-185X.13265","volume":"21","author":"TL Lai","year":"2018","unstructured":"Lai TL, Yim CW, Wong PY et al (2018) Hyperuricemia in Asian psoriatic arthritis patients. Int J Rheum Dis 21:843\u2013849. https:\/\/doi.org\/10.1111\/1756-185X.13265","journal-title":"Int J Rheum Dis"},{"key":"6061_CR10","doi-asserted-by":"publisher","unstructured":"Merola JF, Wu S, Han J, et al. Psoriasis, psoriatic arthritis, and risk of gout in U.S. men and women. Ann Rheum Dis 2015;74:1495\u2013500. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205212","DOI":"10.1136\/annrheumdis-2014-205212"},{"key":"6061_CR11","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.rhum.2020.07.009","volume":"87","author":"T Pascart","year":"2020","unstructured":"Pascart T, Latourte A, Chal\u00e8s G et al (2020) Recommandations de la Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie pour la prise en charge de la goutte: le traitement hypo-uric\u00e9miant. Rev Rhum 87:332\u2013341. https:\/\/doi.org\/10.1016\/j.rhum.2020.07.009","journal-title":"Rev Rhum"},{"key":"6061_CR12","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/acr.24180","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T et al (2020) 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken) 72:744\u2013760. https:\/\/doi.org\/10.1002\/acr.24180","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"6061_CR13","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/art.1780150209","volume":"15","author":"JN Loeb","year":"1972","unstructured":"Loeb JN (1972) The influence of temperature on the solubility of monosodium urate. Arthritis Rheum 15:189\u2013192. https:\/\/doi.org\/10.1002\/art.1780150209","journal-title":"Arthritis Rheum"},{"key":"6061_CR14","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jbspin.2015.01.002","volume":"82","author":"T Bardin","year":"2015","unstructured":"Bardin T (2015) Hyperuricemia starts at 360 micromoles (6 mg\/dL). Joint Bone Spine 82:141\u2013143. https:\/\/doi.org\/10.1016\/j.jbspin.2015.01.002","journal-title":"Joint Bone Spine"},{"key":"6061_CR15","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1136\/annrheumdis-2015-208237","volume":"74","author":"T Neogi","year":"2015","unstructured":"Neogi T, Jansen TLTA, Dalbeth N et al (2015) 2015 Gout classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 74:1789\u20131798. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208237","journal-title":"Ann Rheum Dis"},{"key":"6061_CR16","doi-asserted-by":"publisher","unstructured":"Hyndman D, Liu S, Miner JN. Urate handling in the human body. Curr Rheumatol Rep 2016; 18. https:\/\/doi.org\/10.1007\/s11926-016-0587-7","DOI":"10.1007\/s11926-016-0587-7"},{"key":"6061_CR17","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","volume":"3","author":"JMH Moll","year":"1973","unstructured":"Moll JMH, Wright V (1973) Psoriatic arthritis. Semin Arthritis Rheum 3:55\u201378. https:\/\/doi.org\/10.1016\/0049-0172(73)90035-8","journal-title":"Semin Arthritis Rheum"},{"key":"6061_CR18","doi-asserted-by":"publisher","unstructured":"Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome\u2014a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabetic Medicine 2006;23:469\u201380. https:\/\/doi.org\/10.1111\/j.1464-5491.2006.01858.x","DOI":"10.1111\/j.1464-5491.2006.01858.x"},{"key":"6061_CR19","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","volume":"47","author":"M Charlson","year":"1994","unstructured":"Charlson M, Szatrowski TP, Peterson J et al (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47:1245\u20131251. https:\/\/doi.org\/10.1016\/0895-4356(94)90129-5","journal-title":"J Clin Epidemiol"},{"key":"6061_CR20","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1109\/TAC.1974.1100705","volume":"19","author":"H Akaike","year":"1974","unstructured":"Akaike H (1974) A new look at the statistical model identification. IEEE Trans Autom Control 19:716\u2013723. https:\/\/doi.org\/10.1109\/TAC.1974.1100705","journal-title":"IEEE Trans Autom Control"},{"key":"6061_CR21","first-page":"101","volume":"36","author":"Y-G Tsai","year":"2003","unstructured":"Tsai Y-G, Chang D-M, Kuo S-Y et al (2003) Relationship between human lymphocyte antigen-B27 and clinical features of psoriatic arthritis. J Microbiol Immunol Infect 36:101\u2013104","journal-title":"J Microbiol Immunol Infect"},{"key":"6061_CR22","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1136\/ard.49.5.318","volume":"49","author":"C L\u00f3pez-Larrea","year":"1990","unstructured":"L\u00f3pez-Larrea C, Torre Alonso JC, Rodriguez Perez A et al (1990) HLA antigens in psoriatic arthritis subtypes of a Spanish population. Ann Rheum Dis 49:318\u2013319","journal-title":"Ann Rheum Dis"},{"key":"6061_CR23","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/BOR.0000000000000152","volume":"27","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, Schwartzman S, Husni M (2015) Recognizing and managing comorbidities in psoriatic arthritis. Curr Opin Rheumatol 27:118\u2013126. https:\/\/doi.org\/10.1097\/BOR.0000000000000152","journal-title":"Curr Opin Rheumatol"},{"key":"6061_CR24","doi-asserted-by":"crossref","unstructured":"Catanoso MG, et al. FRI0350\u2005Factors associated with peripheral erosive radiographic disease in a consecutive series of 794 psoriatic arthritis patients. ARD 2020.","DOI":"10.1136\/annrheumdis-2020-eular.6088"},{"key":"6061_CR25","unstructured":"Bardin T, Doherty M, et al. Estimation de la pr\u00e9valence de la goutte en 2013 en France. , M. Doherty et coll. 2013."},{"key":"6061_CR26","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1001\/archderm.1982.01650150073031","volume":"118","author":"JW Burnett","year":"1982","unstructured":"Burnett JW (1982) Acute gout secondary to psoriasis exacerbated by photochemotherapy. Arch Dermatol 118:211\u2013211. https:\/\/doi.org\/10.1001\/archderm.1982.01650150073031","journal-title":"Arch Dermatol"},{"key":"6061_CR27","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1684\/ejd.2008.0607","volume":"19","author":"M Liu","year":"2009","unstructured":"Liu M, Li J-H, Li B et al (2009) Coexisting gout, erythrodermic psoriasis and psoriatic arthritis. Eur J Dermatol 19:184\u2013185. https:\/\/doi.org\/10.1684\/ejd.2008.0607","journal-title":"Eur J Dermatol"},{"key":"6061_CR28","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1590\/abd1806-4841.20174895","volume":"92","author":"LC Lobato","year":"2017","unstructured":"Lobato LC, Coutinho JC, Frota MZM et al (2017) Chronic tophaceous gout in patients with psoriasis. An Bras Dermatol 92:104\u2013106. https:\/\/doi.org\/10.1590\/abd1806-4841.20174895","journal-title":"An Bras Dermatol"},{"key":"6061_CR29","first-page":"213","volume":"7","author":"KV Venkatasubramaniam","year":"1980","unstructured":"Venkatasubramaniam KV, Bluhm GB, Riddle JM (1980) Psoriatic arthropathy and crystal-induced synovitis. J Rheumatol 7:213\u2013217","journal-title":"J Rheumatol"},{"key":"6061_CR30","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1080\/030097498442442","volume":"27","author":"Cosimo De Bari FPC Giovanni Lapadula","year":"1998","unstructured":"Cosimo De Bari FPC Giovanni Lapadula (1998) Coexisting psoriatic arthritis, gout, and chondrocalcinosis: case report. Scand J Rheumatol 27:306\u2013309. https:\/\/doi.org\/10.1080\/030097498442442","journal-title":"Scand J Rheumatol"},{"key":"6061_CR31","doi-asserted-by":"publisher","first-page":"441","DOI":"10.5604\/15093492.1119622","volume":"16","author":"P Morasiewicz","year":"2014","unstructured":"Morasiewicz P, Koprowski P, Dragan S (2014) Coexisting psoriasis, psoriatic arthritis, gout and Dupuytren\u2019s contracture. Ortop Traumatol Rehabil 16:441\u2013447. https:\/\/doi.org\/10.5604\/15093492.1119622","journal-title":"Ortop Traumatol Rehabil"},{"key":"6061_CR32","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/bf02041566","volume":"2","author":"K Bosmansky","year":"1983","unstructured":"Bosmansky K, Trnavsky K (1983) Psoriasis and gout: report of 4 cases. Clin Rheumatol 2:423\u2013426. https:\/\/doi.org\/10.1007\/bf02041566","journal-title":"Clin Rheumatol"},{"key":"6061_CR33","doi-asserted-by":"publisher","unstructured":"Kumar A. U. A, Browne LD, Li X, et al. Temporal trends in hyperuricaemia in the Irish health system from 2006\u20132014: A cohort study. PLoS One 2018;13. https:\/\/doi.org\/10.1371\/journal.pone.0198197","DOI":"10.1371\/journal.pone.0198197"},{"key":"6061_CR34","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1111\/1346-8138.13968","volume":"44","author":"N Tsuruta","year":"2017","unstructured":"Tsuruta N, Imafuku S, Narisawa Y (2017) Hyperuricemia is an independent risk factor for psoriatic arthritis in psoriatic patients. J Dermatol 44:1349\u20131352. https:\/\/doi.org\/10.1111\/1346-8138.13968","journal-title":"J Dermatol"},{"key":"6061_CR35","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13075-020-02173-4","volume":"22","author":"S Li","year":"2020","unstructured":"Li S, Cui L, Cheng J et al (2020) Repeated measurements of serum urate and mortality: a prospective cohort study of 152,358 individuals over 8 years of follow-up. Arthritis Res Ther 22:84. https:\/\/doi.org\/10.1186\/s13075-020-02173-4","journal-title":"Arthritis Res Ther"},{"key":"6061_CR36","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1001\/jama.1968.03150070038006","volume":"206","author":"SV Kasl","year":"1968","unstructured":"Kasl SV, Cobb S, Brooks GW (1968) Changes in serum uric acid and cholesterol levels in men undergoing job loss. JAMA 206:1500\u20131507. https:\/\/doi.org\/10.1001\/jama.1968.03150070038006","journal-title":"JAMA"},{"key":"6061_CR37","doi-asserted-by":"publisher","first-page":"7578","DOI":"10.1038\/s41598-020-64587-z","volume":"10","author":"E Zitt","year":"2020","unstructured":"Zitt E, Fischer A, Lhotta K et al (2020) Sex- and age-specific variations, temporal trends and metabolic determinants of serum uric acid concentrations in a large population-based Austrian cohort. Sci Rep 10:7578. https:\/\/doi.org\/10.1038\/s41598-020-64587-z","journal-title":"Sci Rep"},{"key":"6061_CR38","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/0002-9343(67)90005-8","volume":"42","author":"MJ Maclachlan","year":"1967","unstructured":"Maclachlan MJ, Rodnan GP (1967) Effects of food, fast and alcohol on serum uric acid and acute attacks of gout. Am J Med 42:38\u201357. https:\/\/doi.org\/10.1016\/0002-9343(67)90005-8","journal-title":"Am J Med"},{"key":"6061_CR39","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1111\/nep.13559","volume":"24","author":"MW Kang","year":"2019","unstructured":"Kang MW, Chin HJ, Joo K-W et al (2019) Hyperuricemia is associated with acute kidney injury and all-cause mortality in hospitalized patients. Nephrology 24:718\u2013724. https:\/\/doi.org\/10.1111\/nep.13559","journal-title":"Nephrology"},{"key":"6061_CR40","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1053\/j.ajkd.2017.01.055","volume":"70","author":"AB Vargas-Santos","year":"2017","unstructured":"Vargas-Santos AB, Neogi T (2017) Management of gout and hyperuricemia in CKD. Am J Kidney Dis 70:422\u2013439. https:\/\/doi.org\/10.1053\/j.ajkd.2017.01.055","journal-title":"Am J Kidney Dis"},{"key":"6061_CR41","doi-asserted-by":"publisher","unstructured":"Li X, Miao X, Wang H, et al. Association of serum uric acid levels in psoriasis. Medicine (Baltimore) 2016;95. https:\/\/doi.org\/10.1097\/MD.0000000000003676","DOI":"10.1097\/MD.0000000000003676"},{"key":"6061_CR42","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1093\/ije\/dyu022","volume":"43","author":"J Berkson","year":"2014","unstructured":"Berkson J (2014) Limitations of the application of fourfold table analysis to hospital data. Int J Epidemiol 43:511\u2013515. https:\/\/doi.org\/10.1093\/ije\/dyu022","journal-title":"Int J Epidemiol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06061-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-022-06061-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06061-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T11:06:19Z","timestamp":1651316779000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-022-06061-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,20]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["6061"],"URL":"https:\/\/doi.org\/10.1007\/s10067-022-06061-x","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,20]]},"assertion":[{"value":"2 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was validated on August 24, 2020, by the Strasbourg University Hospital Ethics Committee (CE-2020\u2013134).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Patients were not involved in the design, conduct, reporting, and dissemination plans of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient involvement"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}